Gabapentin Solution
Product Images NDC 65162-698

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 65162-698). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Gabapentin Oral Solution 1)

A formula image displaying the Cockcroft-Gault equation for estimating creatinine clearance (CLCr). It includes variables such as age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplier of 0.85 for female patients.*

FDA Label Image

1 (Gabapentin Oral Solution 2)

Chemical structure diagram of gabapentin, showing its cyclohexane ring attached to amino and carboxyl functional groups, as represented in the generic formulation of gabapentin oral solution.*

FDA Label Image

1 (Gabapentin Oral Solution 3)

Line graph showing mean pain score over 8 weeks for Gabapentin 3600 mg/day compared to placebo. The X-axis represents weeks from baseline to week 8, including a 4-week dose titration period and a 4-week fixed dose period. The Y-axis shows the mean pain score on a scale of 0 to 10. Gabapentin's pain score decreases over time, while placebo pain score remains relatively stable.*

FDA Label Image

1 (Gabapentin Oral Solution 4)

A line graph displaying mean pain scores over a 7-week period, comparing placebo and two doses of gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period, while the y-axis measures mean pain scores from 0 to 10. Data points demonstrate trends for each group across the study duration.*

FDA Label Image

1 (Gabapentin Oral Solution 5)

A bar graph showing results from two studies comparing placebo (PBO) versus Gabapentin (GBP) at different doses. Study 1 shows 12% for PBO and 29% for GBP 3600. Study 2 shows 14% for PBO, 32% for GBP 1800, and 34% for GBP 2400. Statistical significance levels are indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

1 (Gabapentin Oral Solution 6)

A scatter plot comparing percentage difference versus daily dose (mg) for Gabapentin oral solution across three studies labeled 'a', 'b', and 'c'. The x-axis shows daily doses from 600 to 1800 mg, and the y-axis shows difference percentages from 2% to 22%. Different markers represent each study with corresponding labels and positions on the graph.*

FDA Label Image

10 (Gabapentin Oral Solution 7)

Gabapentin Oral Solution 250 mg/5 mL label from Amneal Pharmaceuticals LLC. The label states it contains 250 mg of gabapentin per 5 mL of oral solution in a 473 mL bottle. Instructions include refrigerated storage at 2° to 8°C (36° to 46°F) and a warning to keep out of reach of children. It is marked Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.